Dermacyte™
Dermacyte™ represents a new approach to psoriasis, with a novel, highly differentiated multi-pathway and multi-cellular mode of action.
Psoriasis is a chronic autoimmune inflammatory disorder affecting between 1-5% of the world’s population – more than 100 million people. Although good progress has been made in treating the disease with monoclonal antibodies, there has been a high incidence of resistance to these therapies after 3-4 years.
Pleiotropic effects of DermacyteTM
Dermacyte™ reduces the cytokines that drive psoriasis as well as regulating the inflammatory cytokines associated with its symptoms:
- Modulates multiple T-cell subsets, acting on a range of dysregulated cytokines
- Pleiotropic activity of Dermacyte™ directly targets IL-17, a driver of psoriasis, as well as regulating the inflammatory cytokines associated with symptoms, including IL-31
Existing treatments are mostly mono-pathway agents and target only the symptoms, underlying cause or broad immune-suppression.
We have generated wide-ranging proof of concept data that shows Dermacyte™ inhibits the key cytokines and chemokines in psoriasis, with a highly differentiated activity profile relative to current standard of care agents.